{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:06:36Z","timestamp":1794607596863,"version":"4.9.1"},"reference-count":69,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>Guidelines for monitoring of medications frequently used in the gender-affirming care of transgender and gender-diverse (TGD) adolescents are based on studies in adults or other medical conditions. In this study, we aimed to investigate commonly screened laboratory measurements in TGD adolescents receiving gender-affirming hormone therapy (GAHT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>TGD adolescents were recruited from 4 study sites in the United States before beginning GAHT. Hemoglobin, hematocrit, hemoglobin A1c, alanine transaminase, aspartate aminotransferase, prolactin, and potassium were abstracted from the medical record at baseline and at 6, 12, and 24 months after starting GAHT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Two-hundred and ninety-three participants (68% designated female at birth) with no previous history of gonadotropin-releasing hormone analog use were included in the analysis. Hemoglobin and hematocrit decreased in adolescents prescribed estradiol (\u22121.4 mg\/dL and \u22123.6%, respectively) and increased in adolescents prescribed testosterone (+1.0 mg\/dL and +3.9%) by 6 months after GAHT initiation. Thirteen (6.5%) participants prescribed testosterone had hematocrit &amp;gt; 50% during GAHT. There were no differences in hemoglobin A1c, alanine transaminase, or aspartate aminotransferase. There was a small increase in prolactin after 6 months of estradiol therapy in transfeminine adolescents. Hyperkalemia in transfeminine adolescents taking spironolactone was infrequent and transient if present.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Abnormal laboratory results are rare in TGD adolescents prescribed GAHT and, if present, occur within 6 months of GAHT initiation. Future guidelines may not require routine screening of these laboratory parameters beyond 6 months of GAHT in otherwise healthy TGD adolescents.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2023-064380","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T08:11:05Z","timestamp":1712131865000},"source":"Crossref","is-referenced-by-count":22,"title":["Laboratory Changes During Gender-Affirming Hormone Therapy in Transgender Adolescents"],"prefix":"10.1542","volume":"153","author":[{"given":"Kate","family":"Millington","sequence":"first","affiliation":[{"name":"aDivision of Pediatric Endocrinology and Adolescent Medicine, Hasbro Children\u2019s Hospital, Providence, Rhode Island"},{"name":"bDepartment of Pediatrics, Warren Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"cDivision of Pediatric Endocrinology, Department of Pediatrics, University of California, San Francisco, San Francisco, California"},{"name":"dDivision of Endocrinology & Metabolism, Department of Medicine, University of California, San Francisco, California"},{"name":"eEndocrine and Metabolism Section, San Francisco Veterans Affairs Health Care System, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Olson-Kennedy","sequence":"additional","affiliation":[{"name":"fDivision of Adolescent and Young Adult Medicine, Department of Pediatrics, Keck School of Medicine of University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Garofalo","sequence":"additional","affiliation":[{"name":"gDivision of Adolescent Medicine, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"cDivision of Pediatric Endocrinology, Department of Pediatrics, University of California, San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Ming","family":"Chan","sequence":"additional","affiliation":[{"name":"hDivision of Endocrinology, Department of Pediatrics, Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"issue":"4","key":"2024050102523424500_B1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jsxm.2018.01.016","article-title":"The Amsterdam Cohort of Gender Dysphoria Study (1972\u20132015): trends in prevalence, treatment, and regrets","volume":"15","author":"Wiepjes","year":"2018","journal-title":"J Sex Med"},{"issue":"6","key":"2024050102523424500_B2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00787-019-01394-6","article-title":"Reevaluation of the Dutch approach: are recently referred transgender youth different compared to earlier referrals?","volume":"29","author":"Arnoldussen","year":"2020","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"5","key":"2024050102523424500_B3","doi-asserted-by":"crossref","first-page":"e20191368","DOI":"10.1542\/peds.2019-1368","article-title":"Trends in referrals to a pediatric transgender clinic","volume":"144","author":"Handler","year":"2019","journal-title":"Pediatrics"},{"issue":"3","key":"2024050102523424500_B4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jadohealth.2015.11.010","article-title":"Characteristics of referrals for gender dysphoria over a 13-year period","volume":"58","author":"Chen","year":"2016","journal-title":"J Adolesc Health"},{"issue":"1","key":"2024050102523424500_B5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/08039488.2019.1667429","article-title":"Time trends in referrals to child and adolescent gender identity services: a study in 4 Nordic countries and in the United Kingdom","volume":"74","author":"Kaltiala","year":"2020","journal-title":"Nord J Psychiatry"},{"issue":"11","key":"2024050102523424500_B6","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an endocrine society clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2024050102523424500_B7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of Care for the Health of Transgender and Gender Diverse People, Version 8","volume":"23","author":"Coleman","year":"2022","journal-title":"Int J of Transgend Health"},{"issue":"6","key":"2024050102523424500_B8","doi-asserted-by":"crossref","DOI":"10.1111\/and.12666","article-title":"Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons","volume":"49","author":"Nota","year":"2017","journal-title":"Andrologia"},{"issue":"6","key":"2024050102523424500_B9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/and.12317","article-title":"Diagnosis of prolactinoma in 2 male-to-female transsexual subjects following high-dose cross-sex hormone therapy","volume":"47","author":"Cunha","year":"2015","journal-title":"Andrologia"},{"issue":"6","key":"2024050102523424500_B10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/BF03349744","article-title":"Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy","volume":"18","author":"Garcia","year":"1995","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"2024050102523424500_B11","first-page":"3177","article-title":"Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient","volume":"81","author":"Serri","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024050102523424500_B12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1210\/jcem-66-2-444","article-title":"Estrogen-induced prolactinoma in a man","volume":"66","author":"Gooren","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024050102523424500_B13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/13697130902929559","article-title":"Effect of long-term, high-dose estrogen treatment on prolactin levels: a retrospective analysis","volume":"12","author":"Sathyapalan","year":"2009","journal-title":"Climacteric"},{"issue":"6","key":"2024050102523424500_B14","first-page":"583","article-title":"Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals","volume":"28","author":"Asscheman","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2024050102523424500_B15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2265.1985.tb01081.x","article-title":"Follow-up of prolactin levels in long-term estrogen-treated male-to-female transsexuals with regard to prolactinoma induction","volume":"22","author":"Gooren","year":"1985","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2024050102523424500_B16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4158\/EP-2018-0101","article-title":"Prolactin levels do not rise among transgender women treated with estradiol and spironolactone","volume":"24","author":"Bisson","year":"2018","journal-title":"Endocr Pract"},{"issue":"11","key":"2024050102523424500_B17","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1161\/CIRCULATIONAHA.118.038584","article-title":"Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy","volume":"139","author":"Nota","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"2024050102523424500_B18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/M17-0577","article-title":"Cardiovascular disease among transgender adults receiving hormone therapy: a narrative review","volume":"167","author":"Streed","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"2024050102523424500_B19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1373\/clinchem.2018.292730","article-title":"Impact of hormone therapy on laboratory values in transgender patients","volume":"65","author":"SoRelle","year":"2019","journal-title":"Clin Chem"},{"issue":"3","key":"2024050102523424500_B20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1210\/clinem\/dgaa546","article-title":"Approach to interpreting common laboratory pathology tests in transgender individuals","volume":"106","author":"Cheung","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024050102523424500_B21","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1210\/js.2019-00030","article-title":"The utility of potassium monitoring in gender-diverse adolescents taking spironolactone","volume":"3","author":"Millington","year":"2019","journal-title":"J Endocr Soc"},{"issue":"3","key":"2024050102523424500_B22","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jadohealth.2020.03.028","article-title":"Physiological and metabolic characteristics of a cohort of transgender and gender-diverse youth in the United States","volume":"67","author":"Millington","year":"2020","journal-title":"J Adolesc Health"},{"issue":"5","key":"2024050102523424500_B23","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamapediatrics.2020.5620","article-title":"Association of high-density lipoprotein cholesterol with sex steroid treatment in transgender and gender-diverse youth","volume":"175","author":"Millington","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"6","key":"2024050102523424500_B24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jacl.2021.09.051","article-title":"Lipoprotein subtypes after testosterone therapy in transmasculine adolescents","volume":"15","author":"Millington","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"9","key":"2024050102523424500_B25","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00467-022-05445-0","article-title":"The effect of gender-affirming hormone treatment on serum creatinine in transgender and gender-diverse youth: implications for estimating GFR","volume":"37","author":"Millington","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"2024050102523424500_B26","doi-asserted-by":"crossref","first-page":"e20173742","DOI":"10.1542\/peds.2017-3742","article-title":"Hormonal treatment in young people with gender dysphoria: a systematic review","volume":"141","author":"Chew","year":"2018","journal-title":"Pediatrics"},{"issue":"7","key":"2024050102523424500_B27","doi-asserted-by":"crossref","first-page":"e14434","DOI":"10.2196\/14434","article-title":"Impact of early medical treatment for transgender youth: protocol for the longitudinal, observational trans youth care study","volume":"8","author":"Olson-Kennedy","year":"2019","journal-title":"JMIR Res Protoc"},{"issue":"2","key":"2024050102523424500_B28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.5455\/medarh.2017.71.132-136","article-title":"Effect of cigarette smoking on hematological parameters in healthy population","volume":"71","author":"Malenica","year":"2017","journal-title":"Med Arh"},{"key":"2024050102523424500_B29","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"National Institute of Diabetes and Digestive and Kidney Diseases","year":"2012"},{"key":"2024050102523424500_B30","author":"Stata Statistical Software","year":"2019"},{"issue":"8","key":"2024050102523424500_B31","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1373\/clinchem.2015.240531","article-title":"Complex biological profile of hematologic markers across pediatric, adult, and geriatric ages: establishment of robust pediatric and adult reference intervals on the basis of the Canadian Health Measures Survey","volume":"61","author":"Adeli","year":"2015","journal-title":"Clin Chem"},{"key":"2024050102523424500_B32","volume-title":"Clinical Methods: The History","author":"Billett","year":"1990","edition":"3rd ed."},{"issue":"4","key":"2024050102523424500_B33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/09546634.2019.1662882","article-title":"Abnormal liver function tests in acne patients receiving isotretinoin","volume":"32","author":"Pona","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2024050102523424500_B34","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"National Institute of Diabetes and Digestive and Kidney Diseases","year":"2012"},{"key":"2024050102523424500_B35","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"National Institute of Diabetes and Digestive and Kidney Diseases","year":"2012"},{"issue":"3","key":"2024050102523424500_B36","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4306\/pi.2017.14.3.368","article-title":"Serum prolactin levels in patients with major depressive disorder receiving selective serotonin-reuptake inhibitor monotherapy for 3 months: a prospective study","volume":"14","author":"Park","year":"2017","journal-title":"Psychiatry Investig"},{"issue":"2","key":"2024050102523424500_B37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.9758\/cpn.2017.15.2.181","article-title":"Dose-dependent course of hyperprolactinemic and normoprolactinemic galactorrhea induced by venlafaxine","volume":"15","author":"Camkurt","year":"2017","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"2","key":"2024050102523424500_B38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0025-6196(11)63132-7","article-title":"Reversible galactorrhea and prolactin elevation related to fluoxetine use","volume":"76","author":"Peterson","year":"2001","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"2024050102523424500_B39","first-page":"929","article-title":"Pharmacological causes of hyperprolactinemia","volume":"3","author":"Torre","year":"2007","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"2024050102523424500_B40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jadohealth.2017.08.005","article-title":"Physiologic response to gender-affirming hormones among transgender youth","volume":"62","author":"Olson-Kennedy","year":"2018","journal-title":"J Adolesc Health"},{"issue":"1","key":"2024050102523424500_B41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jalm\/jfaa192","article-title":"Dynamic impact of hormone therapy on laboratory values in transgender patients over time","volume":"6","author":"Allen","year":"2021","journal-title":"J Appl Lab Med"},{"issue":"5","key":"2024050102523424500_B42","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1373\/jalm.2018.027078","article-title":"Common hormone therapies used to care for transgender patients influence laboratory results","volume":"3","author":"Humble","year":"2019","journal-title":"J Appl Lab Med"},{"issue":"5","key":"2024050102523424500_B43","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2265.2003.01753.x","article-title":"Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects","volume":"58","author":"Elbers","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2024050102523424500_B44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4239\/wjd.v11.i3.66","article-title":"Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: a systematic review","volume":"11","author":"Spanos","year":"2020","journal-title":"World J Diabetes"},{"issue":"1","key":"2024050102523424500_B45","first-page":"265","article-title":"Induction of insulin resistance by androgens and estrogens","volume":"79","author":"Polderman","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024050102523424500_B46","doi-asserted-by":"crossref","first-page":"9240569","DOI":"10.1155\/2022\/9240569","article-title":"Association of insulin resistance and elevated androgen levels with polycystic ovarian syndrome (PCOS): a review of literature","volume":"2022","author":"Xu","year":"2022","journal-title":"J Healthc Eng"},{"issue":"3","key":"2024050102523424500_B47","doi-asserted-by":"crossref","first-page":"e704","DOI":"10.1210\/clinem\/dgz029","article-title":"Body composition and markers of cardiometabolic health in transgender youth compared with cisgender youth","volume":"105","author":"Nokoff","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024050102523424500_B48","doi-asserted-by":"crossref","first-page":"e1549","DOI":"10.1210\/clinem\/dgab832","article-title":"Is there a link between hormone use and diabetes incidence in transgender people? Data from the STRONG Cohort","volume":"107","author":"Islam","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024050102523424500_B49","doi-asserted-by":"crossref","first-page":"e2000","DOI":"10.1210\/clinem\/dgab934","article-title":"Incident diabetes risk is not increased in transgender individuals using hormone therapy","volume":"107","author":"van Velzen","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024050102523424500_B50","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2337\/dc08-1128","article-title":"Prevalence of prediabetes and its association with clustering of cardiometabolic risk factors and hyperinsulinemia among US adolescents: National Health and Nutrition Examination Survey 2005\u20132006","volume":"32","author":"Li","year":"2009","journal-title":"Diabetes Care"},{"key":"2024050102523424500_B51","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.2337\/dc20-S013","article-title":"13. Children and adolescents: standards of medical care in diabetes\u20132020","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"key":"2024050102523424500_B52","doi-asserted-by":"crossref","first-page":"bcr02.2009.1589","DOI":"10.1136\/bcr.02.2009.1589","article-title":"Autonomous prolactin secretion in 2 male-to-female transgender patients using conventional estrogen dosages","volume":"2009","author":"Bunck","year":"2009","journal-title":"BMJ Case Rep"},{"issue":"7","key":"2024050102523424500_B53","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/brain\/awy108","article-title":"The occurrence of benign brain tumors in transgender individuals during cross-sex hormone treatment","volume":"141","author":"Nota","year":"2018","journal-title":"Brain"},{"issue":"2","key":"2024050102523424500_B54","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12020-020-02563-3","article-title":"Hyperprolactinemia and association with prolactinoma in transwomen receiving gender affirming hormone treatment","volume":"72","author":"Raven","year":"2021","journal-title":"Endocrine"},{"issue":"11","key":"2024050102523424500_B55","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jsxm.2016.09.012","article-title":"Differential effects of cyproterone acetate vs spironolactone on serum high-density lipoprotein and prolactin concentrations in the hormonal treatment of transgender women","volume":"13","author":"Fung","year":"2016","journal-title":"J Sex Med"},{"issue":"5","key":"2024050102523424500_B56","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1089\/lgbt.2016.0190","article-title":"Transient elevated serum prolactin in trans women is caused by cyproterone acetate treatment","volume":"4","author":"Defreyne","year":"2017","journal-title":"LGBT Health"},{"issue":"5","key":"2024050102523424500_B57","doi-asserted-by":"crossref","first-page":"e20163173","DOI":"10.1542\/peds.2016-3173","article-title":"Cross-sex hormones and metabolic parameters in adolescents with gender dysphoria","volume":"139","author":"Jarin","year":"2017","journal-title":"Pediatrics"},{"issue":"11","key":"2024050102523424500_B58","doi-asserted-by":"crossref","first-page":"bvac133","DOI":"10.1210\/jendso\/bvac133","article-title":"The utility of monitoring potassium in transgender, gender diverse, and nonbinary individuals on spironolactone","volume":"6","author":"Hayes","year":"2022","journal-title":"J Endocr Soc"},{"issue":"11","key":"2024050102523424500_B59","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.eprac.2022.08.007","article-title":"Potassium concentrations in transgender women using spironolactone: a retrospective chart review","volume":"28","author":"Gupta","year":"2022","journal-title":"Endocr Pract"},{"key":"2024050102523424500_B60","article-title":"Potassium","author":"Labcorp"},{"key":"2024050102523424500_B61","article-title":"Potassium, serum","author":"Quest Diagnostics"},{"issue":"2","key":"2024050102523424500_B62","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0030-1255074","article-title":"Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist","volume":"119","author":"Mueller","year":"2011","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"8","key":"2024050102523424500_B63","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/jsm.12571","article-title":"Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence","volume":"11","author":"Wierckx","year":"2014","journal-title":"J Sex Med"},{"issue":"4","key":"2024050102523424500_B64","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4158\/EP15950.OR","article-title":"Metabolic effects of hormone therapy in transgender patients","volume":"22","author":"Fernandez","year":"2016","journal-title":"Endocr Pract"},{"issue":"5","key":"2024050102523424500_B65","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/andr.12382","article-title":"Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review","volume":"5","author":"Velho","year":"2017","journal-title":"Andrology"},{"issue":"3","key":"2024050102523424500_B66","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/andr.12485","article-title":"Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence","volume":"6","author":"Defreyne","year":"2018","journal-title":"Andrology"},{"issue":"5","key":"2024050102523424500_B67","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024050102523424500_B68","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.jsxm.2021.06.011","article-title":"Longitudinal changes in liver enzyme levels among transgender people receiving gender affirming hormone therapy","volume":"18","author":"Hashemi","year":"2021","journal-title":"J Sex Med"},{"issue":"4","key":"2024050102523424500_B69","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1530\/EJE-20-1064","article-title":"Is there a need for liver enzyme monitoring in people using gender-affirming hormone therapy?","volume":"184","author":"Stangl","year":"2021","journal-title":"Eur J Endocrinol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2023-064380\/1623652\/peds.2023-064380.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2023-064380\/1623652\/peds.2023-064380.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T02:53:22Z","timestamp":1714532002000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/153\/5\/e2023064380\/197070\/Laboratory-Changes-During-Gender-Affirming-Hormone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":69,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,4,3]]},"published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2023-064380","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"article-number":"e2023064380"}}